healthy study partlclpants were analyzed by whole-blood aggregometry. Platelet aggregation was determined by the increase in impedance across paired electrodes in response to the aggregatory agents collagen and ADP, respectively. For CV patients, these data were regarded for medication. Blood samples from healthy study participants were studied after addition of ACE inhibitors in different dosage titrations. Results: As the central flnding, platelet aggregation was attenuated ex viva by captopril and ramipril as well as by ASA and clopidogrel. While decrease in collagen-induced platelet aggregation was significant with captopril (24%: P=O.O2) and ramipril (29%; P=O.O3), an adverse increase was seen with enalapril (11%; PcO.05). Following collagen induction, platelet aggregation decreased by 23% (PcO.01) with ASA and with ASAiclopidogrel by 35%
gation was determined by the increase in impedance across paired electrodes in response to the aggregatory agents collagen and ADP, respectively. For CV patients, these data were regarded for medication. Blood samples from healthy study participants were studied after addition of ACE inhibitors in different dosage titrations. Results: As the central flnding, platelet aggregation was attenuated ex viva by captopril and ramipril as well as by ASA and clopidogrel. While decrease in collagen-induced platelet aggregation was significant with captopril (24%: P=O.O2) and ramipril (29%; P=O.O3), an adverse increase was seen with enalapril (11%; PcO.05). Following collagen induction, platelet aggregation decreased by 23% (PcO.01) with ASA and with ASAiclopidogrel by 35%
(P=O.O4). After ADP induction, inhibition with ASA!clopidogrel was 85% (PcO.Ol), with ASA 19% (P=O.O3) and with captoprll there was a trend of inhibition (27%; P=O.l4); no significant antithrombotic effect was seen with ramiprrl or enalapril. In vitro, there was no significant change of platelet aggregation after addition of specific ACE Inhibitors. Ox-LDL upregulates expression of adhesion molecules. such as P-selectin and intracellular adhesion molecule-l (ICAM-1). We hypothesized that fish oil components may reduce ox-LDL-mediated expression of adhesion molecules.
Materials & Methods:
Cultured human coronary artery endothelial cells (fourth ganeration) were incubated with ox-LDL (40&ml) for 24 hrs. Parallel groups of cells were pretreated with docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) (IO and 50 PM), the tw major components of fish oil, for overnight before incubation with ox-LDL.
Another group of cells was treated with the protein kinase B (PKB) inhibitor wortmannin (100 nM) along with DHA (50 pM).
Results: Ox-LDL markedly increased the expression of P-selectin and ICAM-I (both protern and mRNA) in HCAECs, enhanced the adherence of monocytes to the cultured endothelail cells, and inhlbited the activity of PKB. Both EPA and DHA decreased ox-LDL-induced upregulation of P-se&tin and ICAM-I expression and adherence of monocytes, and increased the activity of PKB (all PqO.02 vs. ox-LDL alone, n=6). The effects of 50 pfv' concentration were rnwe pronounced than the effects of IO @l (P<O.O5).
Import&tly, the PKB inhibitor wortmann~n attenuated the effects of DHA (PcO.05).
Conclusions:
The present study shows that both EPA and DHA attenuate the ox-LDLinduced expression of adhesion molecules and the adherence of monocytes to the endothelial cells These effect of EPA and DHA are mediated by modulation of PKB activity. These effects of EPA'DHA may underlie the anti-atherosclerotic effects of fish/ fish oils.
1132-121 Angiotensin
Receptor Type 1 (AT,) Independent Growth Conclusion: Intracellular Ang II promotes cardiac myocyte growth through mechanisms independent of plasma membrane AT, receptor activation and secreted growth factors.
Effects of Intracellular Angiotensin II (Ang II) in Cardiac Myocytes
This observation may represent a second level of control for Ang II mediated growth and provides a potentially important target for therapeutic inten ention. found for the increase in LV mass when analysed for BIAR genotype. The third populabon comprised 249 patients with renal disease with echocardiographically determined LV mass. There was a highly significant difference in LV mass between the GG group when compared to the other 2 groups, CG:GG pqO.05 and CC:GG pcO.01. There were no significant difference in blood pressure measurments, ejection fraction or age between genotypes.Omining those on renal replacement therapy, beta-blockers or ACE inhibitors did not diminish the strength of the association.
1132-122 Genetic Determinants of Left Ventricular Mass: The

Conclusion:
GenetIc variation at the Bl AR locus is of greater importance in defining LV mass in pathologkxl circumstances. Recent data showed that long QT syncrome (LQTS) patrents with mu:ations in the pore region of HERG (LQT2) gene have significantly higher risk of cardiac events than patients with mutations in non-pore region. The aim of this study was to determine whether there IS an association between location of mutations in the KCNQI gene and cardiac events in LQTI patients. Methods. Study population consisted of 216 LQTI patients with KCNQI gene mutation.
1132-123
Demographic, clinical. and follow-up informabon was compared among patients with different location of KCNQI mutations defined as: prs-pore region including N-terminus (I-
